

N-Glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer


Yanrong Wen^{1&}, Xiawen Lin^{1&}, Yuwen Zhou², Lei Xu², Junli Zhang², Cuiying Chen^{2*}, Jian He^{1*}

¹ Department of Nuclear Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China


² Sysdiagno (Nanjing) Biotech Co.,Ltd, Nanjing, China

[&]These authors contributed equally to this work


Correspondence should be addressed to Jian He (hjsxueren@126.com),
Cuiying Chen (chitty.chen@sdbiomed.com).




Supplementary Figure 1 Patients' Characteristics. A: Age distribution; B: Age distribution.




Supplementary Figure 2 The tumor markers were compared among the three groups.



Supplementary Figure 3 Analyses control for (A) age and (B) gender in benign group patients and pancreatic adenocarcinoma patients.



Supplementary Figure 4 Analyses control of (A) age and (B) gender for comparative analysis in a 71-pancreatic cancer patient validation cohort.



Supplementary Figure 5 ROC curves of various tumor markers for discriminating between PDAC and Non-PDAC.

Supplementary Table 1 Diagnostic model performance of the concomitant utilization of N-glycans and tumor markers for PDAC

Biomarkers	AUC
N-glycan combined with CA199	0.919
N-glycan combined with CA125	0.910
N-glycan combined with CEA	0.912
N-glycan combined with CA242	0.861
N-glycan combined with CA724	0.806